Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens

The off-label uses of tigecycline (TGC) to treat ventilator-associated pneumonia (VAP) have aroused worldwide concerns. The efficacy about TGC has been recently reported. However, the adverse events (AEs) remain controversial. Our study aims to analyze the safety of the high-dose (HD) regimens in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zihan, Shi, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160260/
https://www.ncbi.nlm.nih.gov/pubmed/30235740
http://dx.doi.org/10.1097/MD.0000000000012467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160260/
https://www.ncbi.nlm.nih.gov/pubmed/30235740
http://dx.doi.org/10.1097/MD.0000000000012467

Ejemplares similares